First-in-class, covalent, oral small molecule inhibitor targeting IRF5. IRF5 is a genetically validated driver of autoimmune diseases, including systemic lupus erythematosus, Sjö ...
BOSTON, March 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results